GFAP and Alzheimer disease: More recently, different plasma-based biomarkers reflecting the whole spectrum of the A/T/N system (Aβ/pTau/NfL and GFAP) are under investigation for a possible future implementation in the clinical practice, potentially revolutionizing the way AD will be diagnosed and treated in the next future [16–20].